Targeting ribosomal RNA transcription with CX-5461 as a new approach for treating cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1038852

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

We have made the fundamental discovery that ribosomal gene transcription is not simply a 'house keeping' process in cancer cells but is required to maintain malignant cell viability. Strikingly inhibition of ribosomal gene transcription using a novel small molecule inhibitor, CX-5461, shows profound selectivity for malignant cells over normal cells. This proposal will translate these observations into 'first in man' phase 1 clinical trials of CX-5461 for the treatment of blood cancers.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2014

Funding Scheme: Development Grants

Funding Amount: $864,067.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer research | clinical trial | oncology | targeted therapy | transcription

Related Links